Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin
2018-003496-36Phase 4Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2018
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of piperacillin + tazobactam in sepsis and septic shock, sponsored by Hospices Civils de Lyon. Primary endpoints: Association between piperacillin and tazobactam pharmacokinetic parameters and amikacin pharmacokinetics and Population pharmacokinetic models for piperacillin and tazobactam. Started Nov 2018; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2018-003496-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003496-36.